JP2024546018A5 - - Google Patents

Info

Publication number
JP2024546018A5
JP2024546018A5 JP2024527417A JP2024527417A JP2024546018A5 JP 2024546018 A5 JP2024546018 A5 JP 2024546018A5 JP 2024527417 A JP2024527417 A JP 2024527417A JP 2024527417 A JP2024527417 A JP 2024527417A JP 2024546018 A5 JP2024546018 A5 JP 2024546018A5
Authority
JP
Japan
Prior art keywords
hla
cells
magea1
peptide
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049556 external-priority patent/WO2023086480A2/en
Publication of JP2024546018A publication Critical patent/JP2024546018A/ja
Publication of JP2024546018A5 publication Critical patent/JP2024546018A5/ja
Pending legal-status Critical Current

Links

JP2024527417A 2021-11-10 2022-11-10 Ｍａｇｅａ１免疫原性ペプチド、ｍａｇｅａ１免疫原性ペプチドを認識する結合性タンパク質、及びその使用 Pending JP2024546018A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163277924P 2021-11-10 2021-11-10
US63/277,924 2021-11-10
US202263317337P 2022-03-07 2022-03-07
US63/317,337 2022-03-07
US202263342415P 2022-05-16 2022-05-16
US63/342,415 2022-05-16
PCT/US2022/049556 WO2023086480A2 (en) 2021-11-10 2022-11-10 Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024546018A JP2024546018A (ja) 2024-12-17
JP2024546018A5 true JP2024546018A5 (enExample) 2025-11-18

Family

ID=86336428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527417A Pending JP2024546018A (ja) 2021-11-10 2022-11-10 Ｍａｇｅａ１免疫原性ペプチド、ｍａｇｅａ１免疫原性ペプチドを認識する結合性タンパク質、及びその使用

Country Status (11)

Country Link
US (1) US20230270832A1 (enExample)
EP (1) EP4430067A2 (enExample)
JP (1) JP2024546018A (enExample)
KR (1) KR20240112285A (enExample)
AU (2) AU2022268347C1 (enExample)
CA (1) CA3237903A1 (enExample)
CO (1) CO2024007212A2 (enExample)
IL (1) IL312744A (enExample)
MX (1) MX2024005746A (enExample)
TW (1) TW202340224A (enExample)
WO (1) WO2023086480A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116716327B (zh) * 2023-08-04 2023-10-20 科士华(南京)生物技术有限公司 一种构建tcr载体的方法
WO2025090850A1 (en) * 2023-10-27 2025-05-01 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
TWI871128B (zh) * 2023-12-08 2025-01-21 陳乃銘 可準確提供循環腫瘤細胞（ｃｔｃ）所需藥物種類之方法
WO2025217037A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of binding proteins for treatment of solid tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
WO2005115447A2 (en) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Human anti-cancer immunotherapy
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
BR112018071466A2 (pt) * 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
MX2021011462A (es) * 2019-03-25 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
US11464842B1 (en) * 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Similar Documents

Publication Publication Date Title
JP2024546018A5 (enExample)
CN112979783B (zh) 获得肿瘤特异性t细胞受体的方法
EP3241561B1 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
JP2024515646A5 (enExample)
KR20200020681A (ko) Tcr 및 펩티드
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2025084864A (ja) Ｔ細胞受容体の選択
CN113195526B (zh) 针对过继性t细胞疗法中的突变myd88l265p蛋白表位的特异性t细胞受体
US11440956B2 (en) Anti-thyroglobulin T cell receptors
Hill et al. Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a
Nakatsugawa et al. CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
US20190359677A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
Marvel et al. The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL
JP2025518203A (ja) Ｍａｇｅ－ａ１特異的ｔｃｒ及びその用途
JP2023550094A5 (enExample)
US12209137B2 (en) Antigen binding proteins specifically binding CT45
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
Shen et al. Structural and functional characterization of peptide–β2m fused HLA-A2/MART127–35 complexes
EP4223782A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer
Hess et al. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen
WO2026021350A1 (zh) Tcr键合方式的化学操纵方法及其应用
AU2024374117A1 (en) Antigen-recognizing construct capable of binding to a frame peptide and a t cell receptor
KR20250113410A (ko) 자가면역 장애에 대한 환자 선택 및 치료 모니터링
JP2023550154A (ja) サイトケラチンに対する抗腫瘍応答
Manning Antigen recognition by an alloreactive T lymphocyte clone